Quality of life in a clinical trial of highly active antiretroviral therapy alone or with intravenous or subcutaneous lnterleukin-2 administration

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 4, 2005, Pages 428-433

  Martin, Barbara K ^a,e   Wu, Albert W ^a,b   Gelman, Rebecca ^c   Mitsuyasu, Ronald T ^d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

AIDS; Clinical trial; Health related quality of life; Highly active antiretroviral therapy; HIV; Interleukin 2

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2;

ARTICLE; CHILL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FEVER; EDEMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALAISE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SAMPLE SIZE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; QUALITY OF LIFE;

EID: 27944480403     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000182848.45722.b7     Document Type: Article

References (21)

1. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses in interleukin-2 in patients with human immunodeficiency virus infection. N Engl J Med. 1995;332:567-575.
2. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350-1356.
3. Carr A, Emery S, Lloyd A, et al. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. J Infect Dis. 1998;178:992-999.
4. Hengge UR, Goos M, Esser S, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. AIDS. 1998;12(Suppl):F225-F234.
5. Davey RT Jr, Chaitt DG, Albert JM, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis. 1999;179: 849-858.
6. Arnó A, Ruiz L, Juan M, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250/μL CD4 T cells and undetectable plasma virus load. J Infect Dis. 1999;180:56-60.
7. 3. J Infect Dis. 2000;181:1614-1621.
8. Levy Y, Capitant C, Houhou S, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. Lancet. 1999;353:1923-1929.
9. 3: CPCRA 059. J Acquir Immune Defic Syndr. 2002;29:221-231.
10. Levy Y, Durier C, Krzysiek R, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS. 2003;17:343-351.
11. Schwartz DH, Skowtron G, Merigan TC. Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus. J Acquir Immune Defic Syndr. 1991;170:1172-1179.
12. Wu AW ACTG QOL601-602 Health Survey Manual: Adult AIDS Clinical Trials Group. 1998. Forms available at: http://www.fstrf.org/qol/aactg/adult_ ql.html.
13. Coplan PM, Cook JR, Carides GW, et al., for the AIDS Clinical Trials Group 320 Study Team. Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine. Clin Infect Dis. 2004;39:426-433.
14. Mrus JM, Williams PG, Tsevat J, et al. Gender differences in health-related quality of life in patients with HIV/AIDS. Qual Life Res. 2005;14:479-491.
15. Wu AW, Hays RD, Kelly S, et al. Applications of the medical outcomes study health-related quality of life measures in HIV/AIDS. Qual Life Res. 1997;6:531-554.
16. Bozette SA, Hays RD, Berry SH, et al. Derivation and properties of a brief health status assessment instrument for use in HIV disease. J Acquir Immune Defic Syndr. 1995;8:253-265.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
18. Mitsuyasu R, Pollard R, Gelman R, et al. The virologie, immunologic and clinical effects of interleukin-2 with potent antiretroviral therapy in advanced patients with HIV infection: a randomized controlled clinical trial-ACTG 328. (In press).
19. Revicki DA, Wu AW, Brown R. Change in clinical status, health status and health utility outcomes in HIV-infected patients. Med Care. 1995; 33(Suppl):AS173-AS182.
20. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics. 1999;15:141-155.
21. Wu AW, Jacobson DL, Frick K, et al. Validity and responsiveness of the EuroQol as a measure of health-related quality of life in people enrolled in an AIDS clinical trial. Qual Life Res. 2002;11:273-282.